119 related articles for article (PubMed ID: 29967074)
21. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
Mologni L; Redaelli S; Morandi A; Plaza-Menacho I; Gambacorti-Passerini C
Mol Cell Endocrinol; 2013 Sep; 377(1-2):1-6. PubMed ID: 23811235
[TBL] [Abstract][Full Text] [Related]
22. Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold.
Brandt W; Mologni L; Preu L; Lemcke T; Gambacorti-Passerini C; Kunick C
Eur J Med Chem; 2010 Jul; 45(7):2919-27. PubMed ID: 20409618
[TBL] [Abstract][Full Text] [Related]
23. Challenges and Strategies in Precision Medicine for Non-Small-Cell Lung Cancer.
Sacco JJ; Al-Akhrass H; Wilson CM
Curr Pharm Des; 2016; 22(28):4374-85. PubMed ID: 27262325
[TBL] [Abstract][Full Text] [Related]
24. Drosophila Cancer Models Identify Functional Differences between Ret Fusions.
Levinson S; Cagan RL
Cell Rep; 2016 Sep; 16(11):3052-3061. PubMed ID: 27626672
[TBL] [Abstract][Full Text] [Related]
25. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
Gautschi O; Milia J; Filleron T; Wolf J; Carbone DP; Owen D; Camidge R; Narayanan V; Doebele RC; Besse B; Remon-Masip J; Janne PA; Awad MM; Peled N; Byoung CC; Karp DD; Van Den Heuvel M; Wakelee HA; Neal JW; Mok TSK; Yang JCH; Ou SI; Pall G; Froesch P; Zalcman G; Gandara DR; Riess JW; Velcheti V; Zeidler K; Diebold J; Früh M; Michels S; Monnet I; Popat S; Rosell R; Karachaliou N; Rothschild SI; Shih JY; Warth A; Muley T; Cabillic F; Mazières J; Drilon A
J Clin Oncol; 2017 May; 35(13):1403-1410. PubMed ID: 28447912
[TBL] [Abstract][Full Text] [Related]
26. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
[TBL] [Abstract][Full Text] [Related]
27. A Road Map for Precision Cancer Medicine Using Personalized Models.
Picco G; Garnett MJ
Cancer Discov; 2017 May; 7(5):456-458. PubMed ID: 28461408
[TBL] [Abstract][Full Text] [Related]
28. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
Henderson YC; Fredrick MJ; Clayman GL
Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):810-5. PubMed ID: 17709622
[TBL] [Abstract][Full Text] [Related]
29. In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.
Prazeres H; Couto JP; Rodrigues F; Vinagre J; Torres J; Trovisco V; Martins TC; Sobrinho-Simões M; Soares P
Endocr Relat Cancer; 2011 Aug; 18(4):401-12. PubMed ID: 21551259
[TBL] [Abstract][Full Text] [Related]
30. Targeting RET for thyroid cancer therapy.
Lanzi C; Cassinelli G; Nicolini V; Zunino F
Biochem Pharmacol; 2009 Feb; 77(3):297-309. PubMed ID: 19028457
[TBL] [Abstract][Full Text] [Related]
31. Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer.
Ferrara R; Auger N; Auclin E; Besse B
J Thorac Oncol; 2018 Jan; 13(1):27-45. PubMed ID: 29128428
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetically Guided Dosing of Oral Drugs: True Precision Oncology?
Ornstein MC; Rini BI
Clin Cancer Res; 2016 Dec; 22(23):5626-5628. PubMed ID: 27663599
[TBL] [Abstract][Full Text] [Related]
33. The RET proto-oncogene: a potential target for molecular cancer therapy.
Pützer BM; Drosten M
Trends Mol Med; 2004 Jul; 10(7):351-7. PubMed ID: 15242684
[TBL] [Abstract][Full Text] [Related]
34. Discovery of
Mologni L; Dalla Via M; Chilin A; Palumbo M; Marzaro G
ChemMedChem; 2017 Aug; 12(16):1390-1398. PubMed ID: 28639308
[TBL] [Abstract][Full Text] [Related]
35. New approaches for breast cancer: should Ret kinase be considered as a novel therapeutic target?
Birner P; Bartsch R; Schreiber M; Dubsky P; Kenner L
Future Oncol; 2014 Feb; 10(3):333-6. PubMed ID: 24559440
[No Abstract] [Full Text] [Related]
36. Perspective on RET proto-oncogene and thyroid cancer.
Le HN; Norton JA
Cancer J; 2000; 6(2):50-7. PubMed ID: 11069217
[TBL] [Abstract][Full Text] [Related]
37. Development of RET mutant cutaneous angiosarcoma during BRAF inhibitor therapy.
Dai J; Kunder CA; Chu EY; Chan EF; Egan CL; Novoa RA
J Cutan Pathol; 2017 Dec; 44(12):1053-1056. PubMed ID: 28796396
[TBL] [Abstract][Full Text] [Related]
38. Development of RET kinase inhibitors for targeted cancer therapy.
Mologni L
Curr Med Chem; 2011; 18(2):162-75. PubMed ID: 21110809
[TBL] [Abstract][Full Text] [Related]
39. Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor.
Yoon H; Shin I; Nam Y; Kim ND; Lee KB; Sim T
Eur J Med Chem; 2017 Jan; 125():1145-1155. PubMed ID: 27814560
[TBL] [Abstract][Full Text] [Related]
40. Selective inhibition of RET mediated cell proliferation in vitro by the kinase inhibitor SPP86.
Alao JP; Michlikova S; Dinér P; Grøtli M; Sunnerhagen P
BMC Cancer; 2014 Nov; 14():853. PubMed ID: 25409876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]